Sponsors (5)
The bill accelerates federal ability to classify and criminally control emerging designer drugs and strengthens enforcement and labeling clarity—improving interdiction and some legal certainty—at the cost of broader criminal exposure, higher penalties and compliance burdens, reduced judicial oversight, and increased risks to research and medical access.
Law enforcement and customs officials can more quickly identify, temporarily schedule, and interdict novel imported psychoactive substances, enabling faster seizures and prosecutions of clandestine designer-drug shipments.
HHS scientific review is required during the scheduling process, giving expert input that can block or limit permanent control of substances that lack abuse potential and helping protect legitimate medical and research access.
Federal prosecutors and courts gain stronger sentencing tools for large-scale or dangerous import/export offenses, which is intended to deter trafficking and reduce harms (deaths, severe injuries) in affected communities.
People who import, export, or possess Schedule A substances face much longer mandatory prison terms, higher statutory fines, and limits on probation or suspended sentences, which will increase incarceration, financial ruin risks, and costs to taxpayers—disproportionately affecting low-income individuals and racial/ethnic minorities.
The bill authorizes predictive, temporary scheduling decisions with limited judicial review, allowing seizures, arrests, or prosecutions based on projected effects rather than established human-use data and reducing courts' ability to check possibly erroneous or burdensome orders.
Temporary scheduling, labeling controls, and broad scheduling authority can restrict medical and research access to substances (and create regulatory uncertainty), disrupting clinical trials, limiting therapeutic options, and hampering scientific study.
Based on analysis of 16 sections of legislative text.
Adds a new Schedule A for imported or import‑threat substances, creates temporary scheduling, raises import/export penalties, imposes labeling rules, and sets research registration/continuity procedures.
Official title: Amend the Controlled Substances Act to clarify how controlled substance analogues that are imported or offered for import are to be regulated, and for other purposes.
Introduced November 20, 2025 by Charles Ernest Grassley · Last progress November 20, 2025
Creates a new federal “Schedule A” in the Controlled Substances Act for substances imported or offered for import that are chemically similar to scheduled drugs or otherwise predicted to have similar stimulant, depressant, or hallucinogenic effects. Establishes an expedited temporary scheduling process, a pathway and continuity rules for research on newly scheduled substances, new labeling requirements for import/export containers, and much higher criminal penalties for import/export offenses involving Schedule A substances. Also allows resentencing petitions when a Schedule A substance is later removed or downgraded.